Roland R Griffiths is a psychopharmacologist at the Johns Hopkins School of Medicine.[12]He specializes in psychiatry and behavioral sciences.[23]He is a member of Departments of Psychiatry and Neurosciences.[4]
Roland Griffiths, Ph.D., is a Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine.[5]He is the principal investigator of the Johns Hopkins Psilocybin Project.[5]In 2009, he conducted the first major study of drugs and spirituality since the 1970s and has launched several more since.[6]His main line of work has been studying the subjective and behavioral effects of mood-altering drugs, and has written over 360 journal articles and book chapters –e.g.[7]Much of Griffiths' early work with psychedelics at Johns Hopkins has focused on psilocybin, the chemical found in so-called magic mushrooms.[8]He ended up switching his research program to the scientific study of psilocybin and went on to publish a landmark double-blind clinical study of the psychological effects of the compound in 2006.[9]
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
Johns Hopkins School of Medicine
2
718
242
Scientists ain't trippin'. The landmark research was a follow-up to a 2016 John Hopkins trial on 51 cancer patients. It had found that magic mushrooms could relieve depression and anxiety about death in cancer patients for "at least six or seven weeks and very plausibly more than six months," lead researcher Roland Griffiths, a professor of psychiatry and neuroscience at Johns Hopkins School of Medicine, said at the time.[12]
01/30/2020
Cancer patients often experience mental anguish and stress, but a single dose of a hallucinogen found in psychedelic mushrooms, along with psychological counseling, improved their mindset, two studies said Thursday. A similar study by researchers at Johns Hopkins University involving 51 patients also showed big improvements in anxiety and depression. "The most interesting and remarkable finding is that a single dose of psilocybin, which lasts four to six hours, produced enduring decreases in depression and anxiety symptoms, and this may represent a fascinating new model for treating some psychiatric conditions," said Roland Griffiths, professor of behavioral biology in the Departments of Psychiatry and Behavioral Sciences and of Neuroscience at the Johns Hopkins University School of Medicine in a statement. Among those who took part in the Johns Hopkins study, 67 percent said the experience was among the top five meaningful experiences in their lives and 83 percent reported increases in their well-being.[1011]
12/02/2016